Pharmalot… Pharmalittle… Good Morning
1 CommentBy Ed Silverman // October 18th, 2010 // 7:05 am
Welcome back, everyone. We hope your weekend was restful and refreshing. Now, of course, the time has come to brace yourself for the usual routine of meetings and deadlines. We are no different. So please join us for the mandatory cup of stimulation as we peruse the news of the world. Meanwhile, we hope today brings you new insights and rewards. Catch you later…
Pfizer Pays Up To $350M To License Biocon Diabetes Drugs (Dow Jones)
Lilly To Close Singapore Drug Discovery Center (Dow Jones)
Roche Seeks To Broaden Actemra Indications (Reuters)
Lilly Osteoporosis Drug Regrows Jawbone: Study (Reuters)
How An Arizona Town Landed 500 Roche Jobs (Inside Tucson Business)
Man Charged With Stealing From Glaxo (Raleigh News & Observer)
Wyeth Fined Over Hazardous Waste (Irish Times)
Canadians Pay Twice As Much For Generics (PharmaTimes)
Pfizer Expands UK Biotech Packaging Site (InPharma-Technologist)
Merck Proceeds With Wastewater Treatment Plant (Lansdale Reporter)
FDA Approval Of Bydureon Diabetes Med Expected (Dow Jones)
industry insider
Lilly closing down an R&D center in a growing market like Singapore is something that companies typically do when they are in the process of being acquired (Lilly is often rumored to be one such target), and the lowered costs makes them more attractive. It’s the only way I can make sense of this move.